Objectives: We present 3 patients with congenital sensorineural hearing loss (SNHL) caused by novel PTPRQ mutations, including clinical manifestations and phenotypic features. Methods: Two hundred twenty (220) Japanese subjects with SNHL from unrelated and nonconsanguineous families were enrolled in the study. Targeted genomic enrichment with massively parallel DNA sequencing of all known nonsyndromic hearing loss genes was performed to identify the genetic cause of hearing loss. Results: Four novel causative PTPRQ mutations were identified in 3 cases. Case 1 had progressive profound SNHL with a homozygous nonsense mutation. Case 2 had nonprogressive profound SNHL with a compound heterozygous mutation (nonsense and missense mutation). Case 3 had nonprogressive moderate SNHL with a compound heterozygous mutation (missense and splice site mutation). Caloric test and vestibular evoked myogenic potential (VEMP) test showed vestibular dysfunction in Case 1. Conclusion: Hearing loss levels and progression among the present cases were varied, and there seem to be no obvious correlations between genotypes and the phenotypic features of their hearing loss. The PTPRQ mutations appeared to be responsible for vestibular dysfunction.
Introduction
Hearing loss is the most common sensory impairment in humans. Genetic causes account for the largest proportion of congenital sensorineural hearing loss (SNHL). Hearing loss is an extremely heterogeneous disorder, and approximately 75% of hereditary hearing loss is nonsyndromic. Therefore, it is difficult to predict the clinical course on the basis of clinical findings. Genetic testing is one way to resolve this problem. However, due to the extreme heterogeneity of SNHL, much labor and expense are required for analysis when using conventional Sanger sequencing.
Recent advances in targeted genomic enrichment with massively parallel DNA sequencing (TGE+MPS) have made it possible to sequence all known causative genes simultaneously. 1, 2 This technology has been reported to afford an effective approach to the diagnosis of genetic hearing loss, particularly in terms of sensitivity, specificity, and reproducibility. 1 In this study, we performed genetic testing using TGE+MPS to analyze the genetic etiology of Japanese hearing loss patients and identified mutations in the PTPRQ (protein tyrosine phosphatase receptor Q) gene. The PTPRQ gene is one of the latest identified as a cause of nonsyndromic SNHL. The locus had been mapped on chromosome 12q21.31 and was assigned DFNB84. 3 The PTPRQ gene is comprised of 58 exons and encodes the PTPRQ protein, which is one of the membrane proteins localized in the basal region of the stereocilia. [3] [4] [5] The PTPRQ protein has 3 domains: the extracellular domain (fibronectin type 3 domain), the membrane spanning domain (tansmembrane domain), and the cytoplasmic domain (phosphatase domain). 3, 6, 7 The PTPRQ protein is known to play key roles in the regulation of actin filaments reorganization, cell shape changes, and shaft connector formation of hair cell stereocilia. 4, 8, 9 Sakaguchi et al 5 reported that the PTPRQ protein appears to maintain the organization of the cell surface coat and the structure of the overall stereocilia bundle through interactions with Myosin VI.
Until now, only 3 families with PTPRQ mutations have been reported, and most of the phenotypic features remain unclear. 3, 6 Here, we describe 3 Japanese patients with congenital SNHL caused by novel PTPRQ mutations.
Subjects and Methods

Subjects
We recruited 2 groups from a Japanese hearing loss population for this study. All subjects had presumed nonsyndromic SNHL. For each proband, informed consent was obtained to participate in this study, which was approved by the human subjects ethical committee associated with each clinic. Clinical information and blood samples were obtained for each proband and for all consenting affected and unaffected relatives. This study was approved by the Ethical Committee of Shinshu University and Yokohama City University.
The first group: Yokohama samples. Twenty-six (26) Japanese subjects from unrelated and nonconsanguineous families were enrolled. These subjects visited Yokohama City University hospital for examination of hearing loss and participated in this study.
The second group: Shinshu samples. One hundred ninety-four (194) Japanese subjects from unrelated and nonconsanguineous families were ascertained through 33 otolaryngology clinics in 28 prefectures across Japan.
Methods
The First Group: Yokohama Samples
Amplicon library preparation. Amplicon libraries were prepared with an Ion AmpliSeq Custom Panel (Applied Biosystems, Life Technologies, Carlsbad, California, USA) for 63 genes reported to cause nonsyndromic hearing loss according to the manufacturer's instructions. The detailed protocol was described elsewhere. 10 After preparation, the amplicon libraries were diluted to 20 pM, and equal amounts of 6 libraries for 6 patients were pooled for 1 sequence reaction.
Emulsion polymerase chain reaction and sequencing. The emulsion polymerase chain reaction (PCR) and sequencing were performed according to the manufacturer's instructions. The detailed protocol was described elsewhere. 10 MPS was performed with an Ion Torrent Personal Genome Machine (PGM) system using an Ion PGM 200 Sequencing Kit and Ion 318 Chip (Life Technologies).
The Second Group: Shinshu Samples
Targeted genomic enrichment and massively parallel sequencing. TGE of all exons of all genes implicated in nonsyndromic SNHL, including nonsyndromic SNHL mimics, was completed as described, targeting 89 genes as part of the OtoSCOPE v5 platform. Libraries were prepared using a modification of the solution-based Agilent SureSelect target enrichment system (Agilent Technologies, Santa Clara, California, USA). 11 In brief, 3 μg gDNA was randomly fragmented to an average size of 250 bp (Covaris Acoustic Solubilizer; Covaris Inc, Woburn, Massachusetts, USA), fragment ends were repaired, A-tails were added, and sequencing adaptors were ligated before the first amplification. Solid-phase reverse immobilization purifications were performed between each enzymatic reaction. Hybridization and capture with RNA baits was followed by a second amplification before pooling for sequencing. Minimal amplification was used-typically 8 cycles for the prehybridization PCR (range, 8-10 cycles) using NEB Phusion HF Master Mix (New England BioLabs Inc, Ipswich, Massachusetts, USA) and 14 cycles for the posthybridization PCR (range, 12-16 cycles) using Agilent Herculase II Fusion DNA Polymerase. All samples were barcoded and multiplexed before sequencing on either an Illumina MiSeq or HiSeq (Illumina Inc, San Diego, California, USA) in pools of 4 to 6 or 48, respectively, using 100-bp paired-end reads.
Base call and data analysis
The first group: Yokohama samples. The sequence data were mapped against the human genome sequence (build GRCh37/hg19) with a Torrent Mapping Alignment Program. After sequence mapping, the DNA variant regions were piled up with Torrent Variant Caller plug-in software. After variant detection, their effects were analyzed using ANNOVAR software. 12, 13 The missense, nonsense, insertion/deletion, and splicing variants were selected from among the identified variants. Variants were further selected as less than 1% of (1) the 1000 genome database, 14 (2) the 6500 exome variants, 15 (3) the Human Genetic Variation Database (data set for 1208 Japanese exome variants), 16 and (4) the 269 in-house Japanese normal hearing controls. To predict the pathogenicity of missense variants, the following functional prediction software was used; PhyloP, 17 Sorting Intolerant from Tolerant (SIFT), 18 Polymorphism Phenotyping (PolyPhen2), 19 LRT, 20 MutationTaster, 21 and GERP++. 22 The second group: Shinshu samples. Data were analyzed as described using a local installation of the open-source Galaxy software and the following open-source tools: BWA 23 for read mapping, Picard for duplicate removal, GATK 24 for local realignment and variant calling, and NGSRich 25 for enrichment statistics. 2 We reported and annotated variants with custom software.
Variant Confirmation
Candidate mutations were confirmed by Sanger sequencing, and the responsible mutations were identified by segregation analysis using samples from among the patients' family members.
Results
We identified 3 cases that had the causative PTPRQ mutations in this study (220 hearing loss patients).
Mutation Analysis
We identified novel 1 nonsense mutation, 2 missense mutations, and 1 splicing junction mutation in the PTPRQ gene (NM_00145026). Case 1: AG 8960 had a homozygous mutation. This mutation corresponded to c.1261C>T, leading to p.Arg421stop (Figure 1 ). Case 2: SNS 2193 had a compound heterozygous mutation. This mutation corresponded to c.166C>G and 1261C>T, leading to p.Pro56Ala and Arg421Stop (Figure 2 ). Case 3: SNS 2912 had a compound heterozygous mutation. This mutation corresponded to c.6453+3delA and 4046T>C, which leads to p.Met1349Thr ( Figure 3 ). As shown in Figures 1, 2 and 3, Sanger sequencing for family segregation was confirmed for each pedigree. None of these mutations were identified in the 1000 genome database, the 6500 exome variants, or the 1208 Japanese exome variants, in addition to the 269 in-house Japanese normal hearing controls database.
Details of Cases
Case 1 sample: ID no. AG 8960. The affected patient was a 19-year-old male. Newborn hearing screening was not performed at his birth. He had no particular complications in the perinatal period. His parents noticed his speech delay given that he only had a few spoken words at the age of 3. He had been referred to Yokohama City University Hospital, Department of Otolaryngology for hearing examinations. Play audiometry showed bilateral moderate hearing loss that was approximately 50 dBHL in the right ear and 75 dBHL in the left ear, which occurred together with otitis media with effusion. He was promptly fitted for hearing aids bilaterally. As a result of the hearing aids, he acquired age-appropriate spoken language. When he was 14 years old, he was aware of his own deterioration in hearing. Pure-tone audiometry (PTA) showed sloping high frequency SNHL that was on average 75 dBHL in both ears. Over a period of 5 years, his high frequency hearing gradually deteriorated. His hearing loss accelerated, and his hearing aids were ineffective by the time he was 19. Bilateral congenital progressive hearing loss was diagnosed.
He suffered from tinnitus and had no history of vertigo, but his elementary school teachers pointed out that he fell down frequently. Otoscopic examination revealed a normal tympanic membrane. Computed tomography (CT) and magnetic resonance imaging (MRI) of the temporal bone showed no abnormal malformations. Caloric test and the vestibular evoked myogenic potential (VEMP) test were performed at the age of 19 years old. These tests showed a hypo-caloric response on the right side and no caloric response or VEMP response on the left side. His parents, brother, and other relatives had no history of hearing impairment.
He underwent cochlear implantation, MED-EL FLEX28, in his right ear at the age of 19 and obtained adequate hearing level. Preoperative sound field threshold levels with hearing aids were approximately 60 dBSPL at 500 to 2000 Hz. Postoperative sound field threshold levels with cochlear implant were 40 dBSPL at 125 through 4000 Hz.
His pedigree, hearing level, and vestibular test results are shown in Figure 1 .
Case 2 sample: ID no. SNS 2193. The patient was a 16-yearold female. She had no particular complications in the perinatal period. However, at age 1 year, 5 months, her mother suspected hearing loss because of her poor response to sound. She underwent a hearing examination, and an auditory brainstem response (ABR) with click stimuli showed no response to 100 dBnHL in both ears. Conditioned orientation response (COR) audiometry showed a threshold above 90 dBHL in all frequencies.
Congenital severe-profound SNHL was suspected, and she was fitted for bilateral hearing aids at the age of 2. Over a period of 14 years, her hearing loss was unchanged. At the age of 16, PTA showed high frequency sloping profound SNHL. She had no history of vertigo in the following years. CT showed no abnormality of the inner or middle ears. Her parents, sister, brother, and other relatives had no history of hearing impairment. Her pedigree and hearing levels are shown in Figure 2 . at an elementary school health check-up, and she was referred to a general hospital clinic of otolaryngology at the age of 7. PTA showed bilateral moderate hearing loss, approximately 60 dBHL in both ears. She started to wear hearing aids bilaterally. Over a period of 11 years, her hearing loss did not deteriorate. Bilateral moderate SNHL was diagnosed; possibly congenital or early onset was suspected. She suffered from bilateral tinnitus when she turned 11. She had no history of vertigo in the following years. CT showed no abnormality of the inner or middle ears. She had a dizygotic twin, and this twin sister had the same level of SNHL. Her parents and other relatives had no history of hearing impairment. Her pedigree and hearing levels are shown in Figure 3 .
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Discussion
We identified novel causative mutations in the PTPRQ gene as a cause of congenital SNHL in a Japanese population using TGE+MPS.
As shown in Table 1 , there are a total of 12 SNHL cases with PTPRQ mutations, including 3 cases identified in this study and 9 previously reported cases. 3, 6 Each affected family had various degrees of hearing loss severity and progressiveness. With respect to Case 1: AG 8960, he had progressive and profound SNHL mainly affected at high frequencies, with a homozygous nonsense mutation. Four of the 7 cases with homozygous nonsense mutations were described as having severe to profound SNHL: 1 case with a flat audiogram and 3 cases with a down-sloping audiogram. Another 2 Palestinian cases with a homozygous nonsense mutation were described as having moderate SNHL, although clinical information on the deterioration of their hearing was lacking. 4 Schraders et al 3 also reported that hearing loss progressed over a period of 10 to 30 years, becoming profound SNHL in 2 Dutch cases with a homozygous nonsense mutation. Thus, there might be variations in hearing levels and progression even among the cases with homozygous nonsense mutations. Thus, we suspect that there is no obvious correlation between genotypes and the phenotypic features of their hearing loss.
In this study, we performed vestibular assessment (caloric test and VEMP test) for Case 1 only. The caloric test revealed a hypo-response on the right side and no response on the left side. The VEMP test revealed no response on the left side ( Figure 1D ). Schraders et al 3 also reported that caloric test showed either no or hypo-responses on both sides in 4 cases with PTPRQ homozygous mutations. A Ptprq knockout mouse study revealed deformation of the stereocilia and hair bundles in the utricle and defects in the hair bundles in the saccule and ampullae. 26 Vestibular evoked potentials (VsEPs) were absent in the majority of Ptprq knockout mice. 26 These findings suggested that the PTPRQ mutations might cause dysfunctions in the vestibular organs. However, Case 1 had not experienced any episodes of vertigo or dizziness. The reason for this incompatibility is unclear, but the Ptprq knockout mice showed no obvious abnormal behavior, except when swimming. 26 Case 1 received a cochlear implant in the right ear at the age of 19, by which time his hearing loss had gradually become severe. His sound field threshold levels were improved after implantation. We suggest that cochlear implantation could be the intervention of choice for cases with PTPRQ mutations.
This study was the first to identify compound heterozygous mutations. Case 2 had profound SNHL with a compound heterozygote for missense and nonsense mutations. Case 3 had moderate SNHL with a compound heterozygote for splicing site mutation and missense mutation. Taken together with the results of previous reports (Table 1) , there does not appear to be any obvious genotype-phenotype correlation. In summary, we performed TEG+MPS in this study, and we believe this method could be useful for identifying rare causative gene mutations, such as the PTPRQ gene. The PTPRQ mutations also appeared to be responsible for the vestibular dysfunction. However, the vestibular symptoms might be almost unrecognizable, even though vestibular tests showed a hypo-response. The hearing loss caused by the PTPRQ mutations appeared to be congenital. With regard to the hearing levels and progression, we observed variations among 3 cases. More precise studies are necessary for better understanding the molecular basis of the genotypes, and the hearing loss was progressive in some cases, so that the follow-up of the patients needed to be lengthy to clarify their phenotypic features.
